Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPA PV-loop study: Empagliflozin impact on LV stiffness in HFpEF
jRCTs071230020Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of empagliflozin in heart failure with preserved ejection fraction (HFpEF), sponsored by Boehringer Ingelheim. Primary endpoint: Change in LV end-diastolic pressure-volume relationship. Started Feb 2024; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on jRCTs071230020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071230020.